Do SLCO1B3 (T334G) and CYP3A5*3 polymorphisms affect response in Egyptian chronic myeloid leukemia patients receiving imatinib therapy?

References

• Hochhaus A. Chronic myelogenous leukemia (CML) resistance to tyrosine kinase inhibitors. Ann Oncol. 2006;17:274–9.
   Web of Science ®Google Scholar
• Walz C, Sattler M. Novel targeted therapies to overcome imatinib mesylate resistance in chronic myeloid leukemia (CML). Crit Rev Oncol Hematol. 2006;57:145–64.
   PubMed Web of Science ®Google Scholar
• Peng B, Lloyd P, Schran H. Clinical pharmacokinetics of imatinib. Clin Pharmacokinet. 2005;44:879–94.
   PubMed Web of Science ®Google Scholar
• Anthony Au, Ravindran A, Ai Sim G, Fadilah S, Abdul W, Abdul Aziz B. Influence of ABCB1 C3435T and ABCG2 C421A gene polymorphisms in response to imatinib mesylate in chronic myeloid leukemia patients. International Conference on Clean and Green Energy IPCBE (2012), vol. 27. Singapore: IACSIT Press.
   Google Scholar
• Konig J, Seithel A, Gradhand U, Fromm MF. Pharmacogenomics of human OATP transporters. Naunyn-Schmiedeberg's Arch Pharmacol. 2006;372:432–43.
   Google Scholar
• Katrin L, Dietrich K, Jörg K. Mutations in the SLCO1B3 gene affecting the substrate specificity of the hepatocellular uptake transporter OATP1B3 (OATP8). Pharmacogenetics. 2004;14(7):441–52.
   PubMedGoogle Scholar
• Franke RM, Sparreboom A. Inhibition of imatinib transport by uremic toxins during renal failure. J Clin Oncol. 2008;26:4226–7.
   PubMed Web of Science ®Google Scholar
• Nambu T, Hamada A, Nakashima R, Yuki M, Kawaguchi T, Mitsuya H, et al. Association of SLCO1B3 polymorphism with intracellular accumulation of imatinib in leukocytes in patients with chronic myeloid leukemia. Biol Pharm Bull. 2011;34(1):114–9.
   PubMed Web of Science ®Google Scholar
• Smith NF, Marsh S, Scott-Horton TJ, Hamada A, Mielke S, Mross K, et al. Variants in the SLCO1B3 gene: interethnic distribution and association with paclitaxel pharmacokinetics. Clin Pharmacol Ther. 2007;81:76–82.
   PubMed Web of Science ®Google Scholar
• Paulussen A, Lavrijsen K, Bohets H, Hendrickx J, Verhasselt P, Luyten W, et al. Two linked mutations in transcriptional regulatory elements of the CYP3A5 gene constitute the major genetic determinant of polymorphic activity in humans. Pharmacogenetics. 2000;10:415–24.
   PubMedGoogle Scholar
• Sailaja K, Rao DN, Rao DR, Vishnupriya S. Analysis of CYP3A5*3 and CYP3A5*6 gene polymorphisms in Indian chronic myeloid leukemia patients. Asian Pac J Cancer Prev. 2010;11:781–4.
   PubMed Web of Science ®Google Scholar
• Kuehl P, Zhang J, Lin Y, Lamba J, Assem M, Schuetz J, et al. Sequence diversity in CYP3A promoters and characterization of the genetic basis of polymorphic CYP3A5 expression. Nat Genet. 2001;27:383–91.
   PubMed Web of Science ®Google Scholar
• Baccarani M, Saglio G, Goldman J, Hochhaus A, Simonsson B, Appelbaum F, et al. Evolving concepts in the management of chronic myeloid leukemia: recommendations from an expert panel on behalf of the European Leukemia Net. Blood. 2006;108:1809–20.
   PubMed Web of Science ®Google Scholar
• Baccarani M, Cortes J, Pane F, Niederwieser D, Saglio G, Apperley J, et al. Chronic myeloid leukemia: an update of concepts and management recommendations of European Leukemia Net. J Clin Oncol. 2009;27(35):6041–51.
   PubMed Web of Science ®Google Scholar
• Tsujimoto M, Dan Y, Hirata S, Ohtani S, Sawada Y. Influence of SLCO1B3 Gene Polymorphism on the Pharmacokinetics of Digoxin in Terminal Renal Failure. Drug Metab Pharmacokinet. 2008;23(6):406–11.
   PubMed Web of Science ®Google Scholar
• Fukuda T, Onishi S, Fukuen S, Ikenaga Y, Ohno M, Hoshino K, et al. CYP3A5 genotype did not impact on nifedipine disposition in healthy volunteers. Pharmacogenomics J. 2004;4(1):34–9.
   PubMedGoogle Scholar
• Sauna ZE, Kimchi-Sarfaty C, Ambudkar SV, Gottesman MM. Gottesman. Silent polymorphisms speak: how they affect pharmacogenomics and the treatment of cancer. Cancer Res. 2007;67:9609–12.
   PubMed Web of Science ®Google Scholar
• Yamakawa Y, Hamada A, Nakashima R, Yuki M, Hirayama C, Kawaguchi T, et al. Association of genetic polymorphisms in the influx transporter SLCO1B3 and the efflux transporter ABCB1 with imatinib pharmacokinetics in patients with chronic myeloid leukemia. Ther Drug Monit. 2011;33(2):244–50.
   PubMed Web of Science ®Google Scholar
• Liu TC, Lin SF, Chen TP, Chang JG. Polymorphism analysis of CYP3A5 in myeloid leukemia. Oncol Rep. 2002;9(2):327–9.
   PubMed Web of Science ®Google Scholar
• Prachi B, Anil Kumar T, Deepa A. Genetic Polymorphism of CYP3A5 gene in Indian chronic myeloid leukemia patients. Mol Cell Biochem. 2010;336(1–2):49–54.
   PubMed Web of Science ®Google Scholar
• Takahashi N, Miura M, Scott SA, Kagaya H, Kameoka Y, Tagawa H, et al. Influence of CYP3A5 and drug transporter polymorphisms on imatinib trough concentration and clinical response among patients with chronic phase chronic myeloid leukemia. J Human Genet. 2010;55(11):731–7.
   PubMed Web of Science ®Google Scholar
• Tsujimoto M, Hirata S, Dan Y, Ohtani H, Sawada Y. Polymorphisms and Linkage Disequilibrium of the OATP8 (OATP1B3) Gene in Japanese Subjects Drug Metab. Pharmacokinetics. 2006;21(2):165–9.
   Google Scholar
• Kim DH, Sriharsha L, Xu W, Kamel-Reid S, Liu X, Siminovitch K, et al. Clinical relevance of a pharmacogenetic approach using multiple candidate genes to predict response and resistance to imatinib therapy in chronic myeloid. Clin Cancer Res. 2009;15(14):4750–8.
   PubMed Web of Science ®Google Scholar
• Gréen H, Skoglund K, Rommel F, Mirghani RA, Lotfi K. CYP3A activity influences imatinib response in patients with chronic myeloid leukemia: a pilot study on in vivo CYP3A activity. Eur J Clin Pharmacol. 2010;66(4):383–6.
   PubMed Web of Science ®Google Scholar
• Qiang M, Anthony YHLu. Pharmacogenetics, Pharmacogenomics, and Individualized Medicine. Pharmacol Rev. 2011;63(2):437–59.
   PubMed Web of Science ®Google Scholar
• Cohen MH, Williams G, Johnson JR, Duan J, Gobburu J, Rahman A, et al. Approval summary for imatinib mesylate capsules in the treatment of chronic myelogenous leukemia. Clin Cancer Res. 2002;8:935–42.
   PubMed Web of Science ®Google Scholar
• Larson RA, Druker BJ, Guilhot F, O'Brien SG, Riviere GJ, Krahnke T, et al. Imatinib pharmacokinetics and its correlation with response and safety in chronic-phase chronic myeloid leukemia: a subanalysis of the IRIS study. Blood. 2008;111:4022–8.
   PubMed Web of Science ®Google Scholar